Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

• Qi Zhou,
• Yu Zhang,
• Jin Peng,
• Xiaohua Wu,
• Quanren Wang,
• Yunong Gao,
• Ge Lou,
• Huirong Shi,
• Rong Sun,
• Jianqing Zhu,
• Lingfang Xia,
• Mei Pan,
• Wenjing Hu,
• Xianfeng Zhou

Affiliations

Qi Zhou

1 Department of Pediatrics, Sinai Health System, Toronto, Ontario, Canada

Yu Zhang

Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Jin Peng

3 Research Information Solutions and Innovation Research & Development, Abigail Wexner Research Institute at Nationwide Children`s Hospital, Columbus, Ohio, USA

Xiaohua Wu

19 Fudan University Shanghai Cancer Center, Shanghai, China

Quanren Wang

Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China

Yunong Gao

Department of Gynecology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China

Ge Lou

Department of Gynecology, Harbin Medical University Cancer Hospital;

Huirong Shi

Department of Gynecology and Obstetrics

Rong Sun

Department of Gynecology and Obstetrics, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;

Jianqing Zhu

Departments of Gynecological Oncology and

Lingfang Xia

Departments of Gynecologic Oncology, and

Mei Pan

Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, China

Wenjing Hu

Department of Oncology, Nanjing Drum Tower Hospital, Nanjing, China

Xianfeng Zhou

Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China